Medicus Pharma Receives UAE DOH Approval To Begin Phase 2 Trial Of Non-Invasive Therapy For Basal Cell Carcinoma

Medicus Pharma Ltd. announced it has received approval from the UAE Department of Health (DOH) to begin its Phase 2 clinical study (SKNJCT-004) evaluating a non-invasive treatment for basal cell carcinoma (BCC) of the skin. It will be a Phase 2 trial done in 36 patients from four major hospitals in the UAE: Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City and the American Hospital of Dubai. 

The study is designed to assess the efficacy and safety of Medicus’ skin cancer treatment without the need for surgical intervention. Insights Research Organization and Solutions (IROS), a UAE-based contract research organization and part of the M42 healthcare portfolio, is managing the clinical trial.